DE3587698T2 - Pharmazeutische Präparate. - Google Patents
Pharmazeutische Präparate.Info
- Publication number
- DE3587698T2 DE3587698T2 DE88119741T DE3587698T DE3587698T2 DE 3587698 T2 DE3587698 T2 DE 3587698T2 DE 88119741 T DE88119741 T DE 88119741T DE 3587698 T DE3587698 T DE 3587698T DE 3587698 T2 DE3587698 T2 DE 3587698T2
- Authority
- DE
- Germany
- Prior art keywords
- active ingredient
- polymer
- reservoir
- skin
- layer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 28
- 239000013543 active substance Substances 0.000 claims abstract description 26
- 238000007910 systemic administration Methods 0.000 claims abstract description 6
- 239000004480 active ingredient Substances 0.000 claims description 65
- 229920000642 polymer Polymers 0.000 claims description 42
- 239000010410 layer Substances 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 21
- 239000003814 drug Substances 0.000 claims description 17
- 239000002831 pharmacologic agent Substances 0.000 claims description 17
- 125000002091 cationic group Chemical group 0.000 claims description 16
- 239000011159 matrix material Substances 0.000 claims description 11
- 229920000058 polyacrylate Polymers 0.000 claims description 10
- 239000012790 adhesive layer Substances 0.000 claims description 9
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 8
- 239000000853 adhesive Substances 0.000 claims description 8
- 230000001070 adhesive effect Effects 0.000 claims description 7
- 125000004185 ester group Chemical group 0.000 claims description 7
- 239000011505 plaster Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims description 2
- 239000007970 homogeneous dispersion Substances 0.000 claims description 2
- 229920001477 hydrophilic polymer Polymers 0.000 abstract description 13
- 229960000488 tizanidine Drugs 0.000 abstract description 12
- XFYDIVBRZNQMJC-UHFFFAOYSA-N tizanidine Chemical compound ClC=1C=CC2=NSN=C2C=1NC1=NCCN1 XFYDIVBRZNQMJC-UHFFFAOYSA-N 0.000 abstract description 12
- 210000003491 skin Anatomy 0.000 description 45
- 230000035515 penetration Effects 0.000 description 30
- 230000004907 flux Effects 0.000 description 18
- -1 salt anions Chemical class 0.000 description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 229940079593 drug Drugs 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- UUOJIACWOAYWEZ-UHFFFAOYSA-N 1-(tert-butylamino)-3-[(2-methyl-1H-indol-4-yl)oxy]propan-2-yl benzoate Chemical compound C1=CC=C2NC(C)=CC2=C1OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1 UUOJIACWOAYWEZ-UHFFFAOYSA-N 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 229960001035 bopindolol Drugs 0.000 description 7
- 239000011347 resin Substances 0.000 description 7
- 229920005989 resin Polymers 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000004094 surface-active agent Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 6
- 239000004698 Polyethylene Substances 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 229960004958 ketotifen Drugs 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 229920000573 polyethylene Polymers 0.000 description 6
- 239000011241 protective layer Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 5
- 229920000053 polysorbate 80 Polymers 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 4
- 239000004606 Fillers/Extenders Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- ZWUKMNZJRDGCTQ-UHFFFAOYSA-N Tizanidine hydrochloride Chemical compound Cl.ClC=1C=CC2=NSN=C2C=1NC1=NCCN1 ZWUKMNZJRDGCTQ-UHFFFAOYSA-N 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- 229960002881 clemastine Drugs 0.000 description 4
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 239000011888 foil Substances 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 229960002388 tizanidine hydrochloride Drugs 0.000 description 4
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 3
- 239000004925 Acrylic resin Substances 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000019695 Migraine disease Diseases 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 230000000996 additive effect Effects 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 238000010579 first pass effect Methods 0.000 description 3
- 229940074047 glyceryl cocoate Drugs 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 229920000193 polymethacrylate Polymers 0.000 description 3
- WBHHMMIMDMUBKC-QJWNTBNXSA-M ricinoleate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O WBHHMMIMDMUBKC-QJWNTBNXSA-M 0.000 description 3
- 229940066675 ricinoleate Drugs 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 2
- 229920000178 Acrylic resin Polymers 0.000 description 2
- 229920003149 Eudragit® E 100 Polymers 0.000 description 2
- 229920003155 Eudragit® RL 100 Polymers 0.000 description 2
- 229920003159 Eudragit® RS 100 Polymers 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- MMOXZBCLCQITDF-UHFFFAOYSA-N N,N-diethyl-m-toluamide Chemical compound CCN(CC)C(=O)C1=CC=CC(C)=C1 MMOXZBCLCQITDF-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 239000004820 Pressure-sensitive adhesive Substances 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000002313 adhesive film Substances 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 239000000806 elastomer Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical class OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 229920006267 polyester film Polymers 0.000 description 2
- 239000008389 polyethoxylated castor oil Substances 0.000 description 2
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- KPJZHOPZRAFDTN-ZRGWGRIASA-N (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CN(C)C3=C1 KPJZHOPZRAFDTN-ZRGWGRIASA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- FWWOWPGPERBCNJ-UHFFFAOYSA-N 2-hydroxy-4-(2-hydroxyethoxy)-4-oxobutanoic acid Chemical compound OCCOC(=O)CC(O)C(O)=O FWWOWPGPERBCNJ-UHFFFAOYSA-N 0.000 description 1
- XLMXUUQMSMKFMH-UZRURVBFSA-N 2-hydroxyethyl (z,12r)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OCCO XLMXUUQMSMKFMH-UZRURVBFSA-N 0.000 description 1
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- LDOONRJGLKHGJI-UHFFFAOYSA-N Bopindolol malonate Chemical compound OC(=O)CC(O)=O.C1=CC=C2NC(C)=CC2=C1OCC(CNC(C)(C)C)OC(=O)C1=CC=CC=C1 LDOONRJGLKHGJI-UHFFFAOYSA-N 0.000 description 1
- QYOVMAREBTZLBT-KTKRTIGZSA-N CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO QYOVMAREBTZLBT-KTKRTIGZSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XTJFFFGAUHQWII-UHFFFAOYSA-N Dibutyl adipate Chemical compound CCCCOC(=O)CCCCC(=O)OCCCC XTJFFFGAUHQWII-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 150000000047 abietol derivative Chemical class 0.000 description 1
- 230000037374 absorbed through the skin Effects 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000003522 acrylic cement Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 239000003420 antiserotonin agent Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229960004883 bopindolol hydrogen malonate Drugs 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- PMGQWSIVQFOFOQ-YKVZVUFRSA-N clemastine fumarate Chemical compound OC(=O)\C=C\C(O)=O.CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 PMGQWSIVQFOFOQ-YKVZVUFRSA-N 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- DTPCFIHYWYONMD-UHFFFAOYSA-N decaethylene glycol Polymers OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO DTPCFIHYWYONMD-UHFFFAOYSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
- 229940031578 diisopropyl adipate Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-M fumarate(1-) Chemical compound OC(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-M 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 229940100242 glycol stearate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-M malonate(1-) Chemical compound OC(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-M 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 125000004492 methyl ester group Chemical group 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- KPJZHOPZRAFDTN-NQUBZZJWSA-N methysergide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)NC(CO)CC)C2)=C3C2=CN(C)C3=C1 KPJZHOPZRAFDTN-NQUBZZJWSA-N 0.000 description 1
- 229960001186 methysergide Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH100884 | 1984-03-01 | ||
| CH175384 | 1984-04-06 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3587698D1 DE3587698D1 (de) | 1994-02-03 |
| DE3587698T2 true DE3587698T2 (de) | 1994-04-28 |
Family
ID=25686369
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE88119741T Expired - Lifetime DE3587698T2 (de) | 1984-03-01 | 1985-02-22 | Pharmazeutische Präparate. |
| DE85810072T Expired - Lifetime DE3587358T2 (de) | 1984-03-01 | 1985-02-22 | Pharmazeutische zusammensetzungen. |
| DE8888119742T Expired - Lifetime DE3587048T2 (de) | 1984-03-01 | 1985-02-22 | Pharmazeutische praeparate. |
| DE3587794T Expired - Lifetime DE3587794T2 (de) | 1984-03-01 | 1985-02-22 | Pharmazeutische Präparate. |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE85810072T Expired - Lifetime DE3587358T2 (de) | 1984-03-01 | 1985-02-22 | Pharmazeutische zusammensetzungen. |
| DE8888119742T Expired - Lifetime DE3587048T2 (de) | 1984-03-01 | 1985-02-22 | Pharmazeutische praeparate. |
| DE3587794T Expired - Lifetime DE3587794T2 (de) | 1984-03-01 | 1985-02-22 | Pharmazeutische Präparate. |
Country Status (18)
| Country | Link |
|---|---|
| EP (3) | EP0315218B1 (OSRAM) |
| JP (2) | JPH0667835B2 (OSRAM) |
| KR (1) | KR920010392B1 (OSRAM) |
| AT (3) | ATE89750T1 (OSRAM) |
| AU (2) | AU578275B2 (OSRAM) |
| CA (1) | CA1257837A (OSRAM) |
| DE (4) | DE3587698T2 (OSRAM) |
| DK (2) | DK175774B1 (OSRAM) |
| GR (1) | GR850507B (OSRAM) |
| HK (2) | HK157896A (OSRAM) |
| HU (1) | HU197847B (OSRAM) |
| IE (2) | IE81316B1 (OSRAM) |
| IL (1) | IL74446A (OSRAM) |
| MY (1) | MY101919A (OSRAM) |
| NZ (1) | NZ211248A (OSRAM) |
| PH (1) | PH24392A (OSRAM) |
| PT (1) | PT80033B (OSRAM) |
| WO (1) | WO1985003878A1 (OSRAM) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU197847B (en) * | 1984-03-01 | 1989-06-28 | Sandoz Ag | Process for producing therapeutical preparations suitable for transdermatic treating |
| US4713243A (en) * | 1986-06-16 | 1987-12-15 | Johnson & Johnson Products, Inc. | Bioadhesive extruded film for intra-oral drug delivery and process |
| NL8701335A (nl) * | 1986-06-21 | 1988-01-18 | Sandoz Ag | Orale farmaceutische preparaten. |
| DE3643987A1 (de) * | 1986-12-22 | 1988-06-23 | Lohmann Therapie Syst Lts | Basische, wirkstoffdurchlaessige haftklebende polymermasse, insbesondere zum einsatz mit basischen wirkstoffen, verfahren zu ihrer herstellung und ihre verwendung |
| DE3805744C2 (de) * | 1987-03-04 | 1999-09-23 | Novartis Ag | Phenylcarbamate zur Hemmung der Acetylcholinesterase |
| DE3901551A1 (de) * | 1989-01-20 | 1990-07-26 | Lohmann Therapie Syst Lts | Superfizielles therapeutisches system mit einem gehalt an einem antineoplastischen wirkstoff, insbesondere 5-fluoruracil |
| DE4020144A1 (de) * | 1990-06-25 | 1992-01-09 | Lohmann Therapie Syst Lts | Pflaster mit hohem gehalt an weichmachenden inhaltsstoffen |
| DE4116912A1 (de) * | 1991-05-18 | 1992-11-26 | Schering Ag | Mittel zur transdermalen applikation enthaltend ergolin-derivate |
| DE4310012A1 (de) * | 1993-03-27 | 1994-09-29 | Roehm Gmbh | Dermales therapeutisches System aus einer schmelzfähigen Poly(meth)acrylat-Mischung |
| AU4613796A (en) * | 1995-02-10 | 1996-08-27 | Jorg Kreuter | Medicament in particle form |
| US6165988A (en) * | 1995-02-10 | 2000-12-26 | Christian Noe | Medicament in particulate form |
| US7150881B2 (en) | 1997-06-26 | 2006-12-19 | Mylan Technologies, Inc. | Adhesive mixture for transdermal delivery of highly plasticizing drugs |
| DE19950066A1 (de) * | 1999-10-16 | 2001-04-26 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit einem Gehalt an Tulobuterol-hydrochlorid zur Verabreichung des Bronchodilatators Tulobuterol über die Haut |
| EP1170006B8 (en) * | 1999-12-14 | 2008-03-19 | Teikoku Seiyaku Co., Ltd. | Drug for alleviating migraine |
| DE10011447A1 (de) * | 2000-03-10 | 2001-09-20 | Roehm Gmbh | Dispersion mit nichtionischem Emulgator |
| DE10043321B4 (de) * | 2000-08-24 | 2005-07-28 | Neurobiotec Gmbh | Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung |
| DE10053397A1 (de) | 2000-10-20 | 2002-05-02 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
| JP5758290B2 (ja) * | 2009-05-01 | 2015-08-05 | 久光製薬株式会社 | 経皮吸収型製剤 |
| KR101690765B1 (ko) * | 2015-04-17 | 2016-12-28 | 동아제약 주식회사 | 항진균성 활성물질을 포함하는 경피 제제 |
| WO2017037812A1 (ja) * | 2015-08-29 | 2017-03-09 | 株式会社メドレックス | 酸捕捉剤を含有する貼付製剤 |
| WO2018199018A1 (ja) * | 2017-04-26 | 2018-11-01 | ニプロ株式会社 | 経皮吸収型製剤およびその製造方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH653256A5 (en) * | 1981-04-06 | 1985-12-31 | Sandoz Ag | Microemulsion for cutaneous use |
| FR2502951B1 (fr) * | 1981-04-06 | 1985-12-06 | Sandoz Sa | Compositions pharmaceutiques topiques sous forme d'une micro-emulsion |
| WO1983000092A1 (en) * | 1981-07-08 | 1983-01-20 | Key Pharma | Polymeric diffusion matrix containing propranolol |
| CH653550A5 (de) * | 1981-10-20 | 1986-01-15 | Sandoz Ag | Pharmazeutische zusammensetzung zur verzoegerten freigabe eines medikamentes im mundbereich. |
| JPS5925320A (ja) * | 1982-08-02 | 1984-02-09 | Watanabe Yakuhin Kogyo Kk | 薬物投与用貼付剤 |
| HU197847B (en) * | 1984-03-01 | 1989-06-28 | Sandoz Ag | Process for producing therapeutical preparations suitable for transdermatic treating |
-
1985
- 1985-02-21 HU HU851480A patent/HU197847B/hu unknown
- 1985-02-21 AU AU40650/85A patent/AU578275B2/en not_active Expired
- 1985-02-21 KR KR1019850700276A patent/KR920010392B1/ko not_active Expired
- 1985-02-21 WO PCT/EP1985/000061 patent/WO1985003878A1/en not_active Ceased
- 1985-02-21 JP JP60501194A patent/JPH0667835B2/ja not_active Expired - Lifetime
- 1985-02-22 EP EP88119741A patent/EP0315218B1/en not_active Expired - Lifetime
- 1985-02-22 DE DE88119741T patent/DE3587698T2/de not_active Expired - Lifetime
- 1985-02-22 EP EP88119742A patent/EP0315219B1/en not_active Expired - Lifetime
- 1985-02-22 EP EP85810072A patent/EP0155229B1/en not_active Expired - Lifetime
- 1985-02-22 DE DE85810072T patent/DE3587358T2/de not_active Expired - Lifetime
- 1985-02-22 DE DE8888119742T patent/DE3587048T2/de not_active Expired - Lifetime
- 1985-02-22 DE DE3587794T patent/DE3587794T2/de not_active Expired - Lifetime
- 1985-02-22 AT AT85810072T patent/ATE89750T1/de not_active IP Right Cessation
- 1985-02-26 IL IL74446A patent/IL74446A/xx not_active IP Right Cessation
- 1985-02-27 GR GR850507A patent/GR850507B/el not_active IP Right Cessation
- 1985-02-27 NZ NZ211248A patent/NZ211248A/xx unknown
- 1985-02-28 IE IE940083A patent/IE81316B1/en not_active IP Right Cessation
- 1985-02-28 IE IE49385A patent/IE61754B1/en not_active IP Right Cessation
- 1985-02-28 CA CA000475441A patent/CA1257837A/en not_active Expired
- 1985-02-28 PT PT80033A patent/PT80033B/pt unknown
- 1985-02-28 PH PH31924A patent/PH24392A/en unknown
- 1985-10-31 DK DK198505029A patent/DK175774B1/da not_active IP Right Cessation
-
1987
- 1987-06-25 DK DK324687A patent/DK164257C/da not_active IP Right Cessation
- 1987-09-29 MY MYPI87002225A patent/MY101919A/en unknown
-
1988
- 1988-05-25 AU AU16626/88A patent/AU607496B2/en not_active Expired
- 1988-11-26 AT AT88119735T patent/ATE103819T1/de not_active IP Right Cessation
- 1988-11-26 AT AT88119741T patent/ATE98876T1/de not_active IP Right Cessation
-
1994
- 1994-02-28 JP JP6029512A patent/JP2540019B2/ja not_active Expired - Lifetime
-
1996
- 1996-08-22 HK HK157896A patent/HK157896A/en not_active IP Right Cessation
- 1996-12-24 HK HK220096A patent/HK220096A/en not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3587048T2 (de) | Pharmazeutische praeparate. | |
| DE69713989T2 (de) | Fentanyl enthaltendes transdermal-pflaster | |
| DE69010076T2 (de) | Transdermales therapeutisches Mittel. | |
| DE69715049T2 (de) | Tranilast enthaltendes externum und verfahren zu dessen herstellung | |
| DE68907406T2 (de) | Deprenyl zur systemischen transdermalen anwendung. | |
| DE69613463T3 (de) | Filmbildende pharmazeutische zusammensetzungen zur transdermalen verabreichung | |
| DE69430917T2 (de) | 3-l-MENTHOXY-PROPANE-1, 2-DIOL ALS LÖSUNGSVERMITTLER UND EXTERNE ZUBEREITUNG, DIE DIESEN ENTHÄLT | |
| DE69431209T2 (de) | Transdermale prostaglandin-zusammensetzung | |
| EP0439180B1 (de) | Transdermales therapeutisches System mit dem Wirkstoff Tulobuterol | |
| EP0341202B1 (de) | Transdermale Monolithsysteme | |
| DE68907858T2 (de) | Arzneizubereitungen zur transdermalen Verabreichung von Wirkstoffen. | |
| EP0186019B1 (de) | Wirkstoffpflaster | |
| DE60304477T2 (de) | Verbessertes transdermales abgabesystem für die verabreichung von rotigotin | |
| DE3880212T2 (de) | Pharmazeutische zusammensetzung zur hautabsorption und hautabsorptionsverstaerkung von medikamenten. | |
| DE69205010T2 (de) | Transdermales estradiol als therapeutisches system. | |
| DE60311449T2 (de) | Transdermales therapeutisches system mit zwei übereinanderliegenden matrixschichten, die verschiedene affinitäten zum enthaltenen wirkstoff ausweisen | |
| DE69229506T2 (de) | Ketorolac enthaltender warmer umschlag | |
| DE68917292T2 (de) | Transdermales estradiol als therapeutisches sytem. | |
| DE60025807T2 (de) | Transdermale zusammenstellung eines antibrechmittels und eine zubereitung die dasselbe enthält | |
| DE3729299A1 (de) | Transdermales therapeutisches system | |
| EP0538433A1 (de) | Mittel zur transdermalen applikation enthaltend ergolin-derivate | |
| DE60309329T2 (de) | Verbessertes transdermales abgabesystem | |
| DE69322328T2 (de) | Transdermal Alfuzosin enthaltendes Arztneimittel | |
| DE3905051C2 (OSRAM) | ||
| DE60101206T2 (de) | Transdermale verabreichung von lasofoxifen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: NOVARTIS AG, BASEL, CH LTS LOHMANN THERAPIE-SYSTEM |